# Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

> **NCT07733674** · PHASE1 · RECRUITING · sponsor: **Radiomedix, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Glioblastoma Multiforme (GBM)
- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **DRUG:** 203Pb-RMX-VHPIB injection
- **DIAGNOSTIC_TEST:** SPECT/CT Imaging

## Key facts

- **NCT ID:** NCT07733674
- **Lead sponsor:** Radiomedix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733674, "Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*